{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:52:39Z","timestamp":1789523559341,"version":"build-2803163510"},"reference-count":71,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P01 CA 066996"],"award-info":[{"award-number":["P01 CA 066996"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Progress in the treatment of multiple myeloma (MM) has resulted in improvement in the survival rate. However, there is still a need for more efficacious and tolerated therapies. We and others have shown that bromodomain-containing protein 9 (BRD9), a member of the non-canonical SWI\/SNF chromatin remodeling complex, plays a role in MM cell survival, and targeting BRD9 selectively blocks MM cell proliferation and synergizes with IMiDs. We found that synergy in vitro is associated with the downregulation of MYC and Ikaros proteins, including IKZF3, and overexpression of IKZF3 or MYC could partially reverse synergy. RNA-seq analysis revealed synergy to be associated with the suppression of pathways associated with MYC and E2F target genes and pathways, including cell cycle, cell division, and DNA replication. Stimulated pathways included cell adhesion and immune and inflammatory response. Importantly, combining IMiD treatment and BRD9 targeting, which leads to the downregulation of MYC protein and upregulation of CRBN protein, was able to override IMiD resistance of cells exposed to iberdomide in long-term culture. Taken together, our results support the notion that combination therapy based on agents targeting BRD9 and IKZF3, two established dependencies in MM, represents a promising novel therapeutic strategy for MM and IMiD-resistant disease.<\/jats:p>","DOI":"10.3390\/cancers16071319","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T12:09:40Z","timestamp":1711627780000},"page":"1319","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma"],"prefix":"10.3390","volume":"16","author":[{"given":"Basudev","family":"Chowdhury","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3719-4342","authenticated-orcid":false,"given":"Swati","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5729-827X","authenticated-orcid":false,"given":"Wei","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5053-4199","authenticated-orcid":false,"given":"Martin","family":"Sattler","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisei","family":"Akatsu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Stone","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Forrester","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, 4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Harrington","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, 4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara J.","family":"Buhrlage","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Griffin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Weisberg","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"key":"ref_1","unstructured":"(2023). Cancer Stat Facts: Myeloma, National Cancer Institute."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CCO.0000000000000615","article-title":"The microenvironment in myeloma","volume":"32","author":"Lomas","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.beha.2007.09.008","article-title":"From the bench to the bedside: Emerging new treatments in multiple myeloma","volume":"20","author":"Mitsiades","year":"2007","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","article-title":"Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma","volume":"124","author":"Zhu","year":"2014","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/205873920601900107","article-title":"c-MYC deregulation is involved in melphalan resistance of multiple myeloma: Role of PDGF-BB","volume":"19","author":"Greco","year":"2006","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.3324\/haematol.2017.186601","article-title":"Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients","volume":"103","author":"Franssen","year":"2018","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kortum","year":"2016","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","volume":"137","author":"Gooding","year":"2021","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1146\/annurev.cellbio.22.010305.104154","article-title":"The biology of cancer stem cells","volume":"23","author":"Lobo","year":"2007","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/leu.2012.197","article-title":"Immunoglobulin heavy\/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients","volume":"27","author":"Ludwig","year":"2013","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/B978-0-12-397927-8.00006-3","article-title":"Emerging strategies for targeting cell adhesion in multiple myeloma","volume":"65","author":"Nair","year":"2012","journal-title":"Adv. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/bjh.18654","article-title":"Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies","volume":"200","author":"Minakata","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clml.2021.10.013","article-title":"Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"22","author":"Costa","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2013-05-484782","article-title":"Pomalidomide","volume":"122","author":"Lacy","year":"2013","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"20406207221090089","DOI":"10.1177\/20406207221090089","article-title":"Pomalidomide- and dexamethasone-based regimens in the treatment of refractory\/relapsed multiple myeloma","volume":"13","author":"Fotiou","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/nchembio.2115","article-title":"Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition","volume":"12","author":"Hohmann","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41419-019-1570-9","article-title":"BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition","volume":"10","author":"Liu","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.21037\/tcr-21-42","article-title":"Targeting BRD9 by I-BRD9 efficiently inhibits growth of acute myeloid leukemia cells","volume":"10","author":"Zhou","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41408-022-00704-7","article-title":"BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma","volume":"12","author":"Weisberg","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1158\/1078-0432.CCR-22-3668","article-title":"BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma","volume":"29","author":"Kurata","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1021\/acs.jmedchem.5b01865","article-title":"Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor","volume":"59","author":"Martin","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Cornwell, M., Vangala, M., Taing, L., Herbert, Z., Koster, J., Li, B., Sun, H., Li, T., Zhang, J., and Qiu, X. (2018). VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis. BMC Bioinform., 19.","DOI":"10.1186\/s12859-018-2139-9"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 15.","DOI":"10.1186\/s13059-014-0550-8"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Garcia-Moreno, A., Lopez-Dominguez, R., Villatoro-Garcia, J.A., Ramirez-Mena, A., Aparicio-Puerta, E., Hackenberg, M., Pascual-Montano, A., and Carmona-Saez, P. (2022). Functional Enrichment Analysis of Regulatory Elements. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030590"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"W130","DOI":"10.1093\/nar\/gkx356","article-title":"WebGestalt 2017: A more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","article-title":"Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412","volume":"1","author":"Weisberg","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Garcia-Gutierrez, L., Delgado, M.D., and Leon, J. (2019). MYC Oncogene Contributions to Release of Cell Cycle Brakes. Genes, 10.","DOI":"10.3390\/genes10030244"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1097-2765(00)00071-X","article-title":"E2F4 and E2F5 play an essential role in pocket protein-mediated G1 control","volume":"6","author":"Gaubatz","year":"2000","journal-title":"Mol. Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1097-2765(01)00275-1","article-title":"Myc requires distinct E2F activities to induce S phase and apoptosis","volume":"8","author":"Leone","year":"2001","journal-title":"Mol. Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1038\/onc.2008.55","article-title":"A role for Myc in facilitating transcription activation by E2F1","volume":"27","author":"Leung","year":"2008","journal-title":"Oncogene"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1210\/en.2003-0388","article-title":"Overexpression of activin beta(C) or activin beta(E) in the mouse liver inhibits regenerative deoxyribonucleic acid synthesis of hepatic cells","volume":"144","author":"Chabicovsky","year":"2003","journal-title":"Endocrinology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/carcin\/bgg154","article-title":"Expression of activins C and E induces apoptosis in human and rat hepatoma cells","volume":"24","author":"Vejda","year":"2003","journal-title":"Carcinogenesis"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"642547","DOI":"10.3389\/fonc.2021.642547","article-title":"The Role of the Transcription Factor EGR1 in Cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1073\/pnas.1008848108","article-title":"Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism","volume":"108","author":"Boone","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1084\/jem.20160553","article-title":"Egr2 and 3 control adaptive immune responses by temporally uncoupling expansion from T cell differentiation","volume":"214","author":"Miao","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41418-022-01088-8","article-title":"The JNK-EGR1 signaling axis promotes TNF-alpha-induced endothelial differentiation of human mesenchymal stem cells via VEGFR2 expression","volume":"30","author":"Jung","year":"2023","journal-title":"Cell Death Differ."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbrc.2013.02.058","article-title":"NFkappaB and MAPK signalling pathways mediate TNFalpha-induced Early Growth Response gene transcription leading to aromatase expression","volume":"433","author":"To","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.4049\/jimmunol.1500016","article-title":"GIMAP GTPase family genes: Potential modifiers in autoimmune diabetes, asthma, and allergy","volume":"194","author":"Heinonen","year":"2015","journal-title":"J. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s12276-020-00506-6","article-title":"Stat2 stability regulation: An intersection between immunity and carcinogenesis","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-019-0173-0","article-title":"Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4","volume":"9","author":"Zhu","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2586","article-title":"Multiple myeloma: Every year a new standard?","volume":"37","author":"Rajkumar","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"9130608","DOI":"10.1155\/2017\/9130608","article-title":"Cereblon: A Protein Crucial to the Multiple Functions of Immunomodulatory Drugs as well as Cell Metabolism and Disease Generation","volume":"2017","author":"Shi","year":"2017","journal-title":"J. Immunol. Res."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Ioannou, N., Jain, K., and Ramsay, A.G. (2021). Immunomodulatory Drugs for the Treatment of B Cell Malignancies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168572"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1002\/anie.201611281","article-title":"Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands","volume":"56","author":"Remillard","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e41305","DOI":"10.7554\/eLife.41305","article-title":"Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma","volume":"7","author":"Brien","year":"2018","journal-title":"eLife"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Wang, X., Yu, J., Yan, J., Peng, K., and Zhou, H. (2022). Single-cell sequencing reveals MYC targeting gene MAD2L1 is associated with prostate cancer bone metastasis tumor dormancy. BMC Urol., 22.","DOI":"10.1186\/s12894-022-00991-z"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12032-015-0633-8","article-title":"The c-Myc-LDHA axis positively regulates aerobic glycolysis and promotes tumor progression in pancreatic cancer","volume":"32","author":"He","year":"2015","journal-title":"Med. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/nar\/29.2.397","article-title":"The transcriptional program of a human B cell line in response to Myc","volume":"29","author":"Schuhmacher","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Nepon-Sixt, B.S., Bryant, V.L., and Alexandrow, M.G. (2019). Myc-driven chromatin accessibility regulates Cdc45 assembly into CMG helicases. Commun. Biol., 2.","DOI":"10.1038\/s42003-019-0353-2"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Yamaguchi, K., Yamaguchi, R., Takahashi, N., Ikenoue, T., Fujii, T., Shinozaki, M., Tsurita, G., Hata, K., Niida, A., and Imoto, S. (2014). Overexpression of cohesion establishment factor DSCC1 through E2F in colorectal cancer. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085750"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Chen, Q., Yang, S., Zhang, Y., Li, B., Xu, H., and Zuo, S. (2022). Identification of MAD2L1 as a Potential Biomarker in Hepatocellular Carcinoma via Comprehensive Bioinformatics Analysis. BioMed Res. Int., 2022.","DOI":"10.1155\/2022\/9868022"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Chen, Y.U., Yu, Y., Lv, M., Shi, Q., and Li, X. (2022). E2F1-mediated up-regulation of TOP2A promotes viability, migration, and invasion, and inhibits apoptosis of gastric cancer cells. J. Biosci., 47.","DOI":"10.1007\/s12038-022-00322-2"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/cas.13867","article-title":"DEP domain containing 1 predicts prognosis of hepatocellular carcinoma patients and regulates tumor proliferation and metastasis","volume":"110","author":"Qu","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.21037\/tcr-22-1701","article-title":"Expressional and functional characteristics of checkpoint kinase 1 as a prognostic biomarker in hepatocellular carcinoma","volume":"11","author":"Bai","year":"2022","journal-title":"Transl. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1025970","DOI":"10.3389\/fgene.2022.1025970","article-title":"Integrative pan-cancer landscape of MMS22L and its potential role in hepatocellular carcinoma","volume":"13","author":"Guo","year":"2022","journal-title":"Front. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1080\/16078454.2022.2124694","article-title":"Mechanism of immunomodulatory drug resistance and novel therapeutic strategies in multiple myeloma","volume":"27","author":"Zuo","year":"2022","journal-title":"Hematology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"106398","DOI":"10.1016\/j.leukres.2020.106398","article-title":"A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma","volume":"95","author":"Kim","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Mendy","year":"2012","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.2174\/1381612822666160307151409","article-title":"Perspective on Nanoparticle Technology for Biomedical Use","volume":"22","author":"Raliya","year":"2016","journal-title":"Curr. Pharm. Des."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/7\/1319\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:20:08Z","timestamp":1760106008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/7\/1319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":71,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cancers16071319"],"URL":"https:\/\/doi.org\/10.3390\/cancers16071319","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]}}}